Non-antibiotic therapies for CAP

European Respiratory Monograph

Volumn 63, Issue , 2014, Pages 219-233

  Faverio, Paola ^a   Restrepo, Marcos I ^b,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTITUSSIVE AGENT; ATORVASTATIN; CLOPIDOGREL; DECONGESTIVE AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROTRECOGIN; EXPECTORANT AGENT; HEPARIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCORTISONE; IBUPROFEN; IMMUNOGLOBULIN; INTERLEUKIN 6; MUCOLYTIC AGENT; NITRIC OXIDE; NON PRESCRIPTION DRUG; PLACEBO; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TERBUTALINE;

AIRWAY; ARTICLE; BREATHING EXERCISE; COMMUNITY ACQUIRED PNEUMONIA; HUMAN; MEDICAL PROCEDURES; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHYSIOTHERAPY; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME;

EID: 84905732748     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10004513     Document Type: Article

References (92)

1. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA2005; 294: 1255-1259.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
3. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009; 57: 1-134.
4. Sibila O, Restrepo MI, Anzueto A. What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents). Infect Dis Clin North Am 2013; 27: 133-147.
5. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-247.
6. Wunderink RG, Laterre P-F, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011; 183: 1561-1568.
7. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
8. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-2064.
9. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912-918.
10. Oz F, Gul S, Kaya MG, et al. Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. Coron Artery Dis 2013; 24: 231-237.
11. Kruger P, Bailey M, Bellomo R, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013; 187: 743-750.
12. Patel JM, Snaith C, Thickett DR, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012; 16: R231.
13. Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37: 1185-1196.
14. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. GINA, 2012. www. ginasthma. org/documents/4 Date last updated: December 2012. Date last accessed: January 13, 2014.
15. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. GOLD, 2013. www. goldcopd. org/guidelines-global-strategy-for-diagnosis-management. html Date last updated: February 2013. Date last accessed: January 13, 2014.
16. Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J2007; 30: 951-956.
17. Salluh JIF, Soares M, Coelho LM, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care 2011; 26: 193-200.
18. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242-248.
19. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007; 185: 249-255.
20. Snijders D, Daniels JMA, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181: 975-982.
21. Meijvis SCA, Hardeman H, Remmelts HHF, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 2023-2030.
22. Fernández-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011; 15: R96.
23. Nie W, Zhang Y, Cheng J, et al. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One 2012; 7: e47926.
24. Shafiq M, Mansoor MS, Khan AA, et al. Adjuvant steroid therapy in community-acquired pneumonia: a systematic review and meta-analysis. J Hosp Med 2013; 8: 68-75.
25. Chen Y, Li K, Pu H, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2011; 3: CD007720.
26. Merx MW, Weber C. Statins in the intensive care unit. Curr Opin Crit Care 2006; 12: 309-314.
27. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
28. Meijvis SCA, van de Garde EMW, Rijkers GT, et al. Treatment with anti-inflammatory drugs in community-acquired pneumonia. J Intern Med 2012; 272: 25-35.
29. Troeman DPR, Postma DF, van Werkhoven CH, et al. The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Infect 2013; 67: 93-101.
30. Falagas ME, Makris GC, Matthaiou DK, et al. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008; 61: 774-785.
31. Wunderink RG, Mandell L. Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med 2012; 33: 311-318.
32. Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-1667.
33. Chopra V, Rogers MAM, Buist M, et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 2012; 125: 1111-1123.
34. Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121: 1002-1007.
35. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ2006; 333: 999.
36. Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011; 39: 1871-1878.
37. Shrank WH, Polinski JM. Medicare Part D-lessons learned and guidance for health-care reform. J Gen Intern Med 2010; 25: 3-4.
38. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012; 125: 773-781.
39. Corrales-Medina VF, Musher DM, Shachkina S, et al. Acute pneumonia and the cardiovascular system. Lancet 2013; 381: 496-505.
40. Maroney SA, Mast AE. Tissue factor pathway inhibitor and bacterial infection. J Thromb Haemost 2011; 9: 119-121.
41. Van Den Boogaard FE, Brands X, Schultz MJ, et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011; 9: 122-132.
42. Laterre P-F. Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition. Crit Care 2008; 12: Suppl. 6, S4.
43. Siempos II, Vardakas KZ, Kopterides P, et al. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008; 62: 661-668.
44. Laterre P-F, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33: 952-961.
45. Winning J, Reichel J, Eisenhut Y, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009; 20: 50-57.
46. Gross AK, Dunn SP, Feola DJ, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013; 35: 147-154.
47. Arons MM, Wheeler AP, Bernard GR, et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 1999; 27: 699-707.
48. Light RB. Indomethacin and acetylsalicylic acid reduce intrapulmonary shunt in experimental pneumococcal pneumonia. Am Rev Respir Dis 1986; 134: 520-525.
49. Voiriot G, Dury S, Parrot A, et al. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest 2011; 139: 387-394.
50. Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect 2011; 63: 187-199.
51. Bugl S, Wirths S, Müller MR, et al. Current insights into neutrophil homeostasis. Ann N Y Acad Sci 2012; 1266: 171-178.
52. Cheng AC, Stephens DP, Currie BJ. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2007; 2: CD004400.
53. Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31: 367-373.
54. Wunderink R, Leeper K Jr, Schein R, et al. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001; 119: 523-529.
55. Nelson S, Heyder AM, Stone J, et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 2000; 182: 970-973.
56. Hartung H-P, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins (IVIg)-beyond immunodeficiencies and neurology. Clin Exp Immunol 2009; 158: Suppl. 1, 23-33.
57. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007; 35: 2686-2692.
58. Turgeon AF, Hutton B, Fergusson DA, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007; 146: 193-203.
59. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
60. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: Suppl. 2, e419S-e494S.
61. Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110: 451-457.
62. Cornet AD, Smit EGM, Beishuizen A, et al. The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007; 98: 579-586.
63. Tuinman PR, Dixon B, Levi M, et al. Nebulized anticoagulants for acute lung injury-a systematic review of preclinical and clinical investigations. Crit Care 2012; 16: R70.
64. Rafailidis PI, Matthaiou DK, Varbobitis I, et al. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol 2008; 64: 565-573.
65. Van der Maarel-Wierink CD, Vanobbergen JNO, Bronkhorst EM, et al. Risk factors for aspiration pneumonia in frail older people: a systematic literature review. J Am Med Dir Assoc 2011; 12: 344-354.
66. Shinohara Y, Origasa H. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. Adv Ther 2012; 29: 900-912.
67. Liu C-L, Shau W-Y, Wu C-S, et al. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients. J Hypertens 2012; 30: 2223-2229.
68. Okaishi K, Morimoto S, Fukuo K, et al. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Am J Hypertens 1999; 12: 778-783.
69. Takahashi T, Morimoto S, Okaishi K, et al. Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the angiotensin I-converting enzyme gene. Am J Hypertens 2005; 18: 1353-1359.
70. Mortensen EM, Restrepo MI, Anzueto A, et al. The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. BMC Pulm Med 2005; 5: 12.
71. van de Garde EMW, Souverein PC, Hak E, et al. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens 2007; 25: 235-239.
72. Mukamal KJ, Ghimire S, Pandey R, et al. Antihypertensive medications and risk of community-acquired pneumonia. J Hypertens 2010; 28: 401-405.
73. Mortensen EM, Restrepo MI, Copeland LA, et al. Association of hydrophilicversuslipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality. Am J Med Sci 2008; 336: 462-466.
74. Caldeira D, Alarcão J, Vaz-Carneiro A, et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ2012; 345: e4260.
75. Lipchik RJ. ACP Journal Club. Review: ACE inhibitors reduce risk for pneumonia. Ann Intern Med 2012; 157: JC5-2.
76. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55: 1466-1473.
77. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
78. Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev 2012; 2: CD006088.
79. Yang M, Yan Y, Yin X, et al. Chest physiotherapy for pneumonia in adults. Cochrane Database Syst Rev 2013; 2: CD006338.
80. Agrafiotis M. Insufficient evidence to recommend routine adjunctive chest physiotherapy for adults with pneumonia. Evid Based Med 2010; 15: 76-77.
81. Pattanshetty RB, Gaude GS. Effect of multimodality chest physiotherapy on the rate of recovery and prevention of complications in patients with mechanical ventilation: a prospective study in medical and surgical intensive care units. Indian J Med Sci 2011; 65: 175-185.
82. Castro AAM, Calil SR, Freitas SA, et al. Chest physiotherapy effectiveness to reduce hospitalization and mechanical ventilation length of stay, pulmonary infection rate and mortality in ICU patients. Respir Med 2013; 107: 68-74.
83. Stiller K. Physiotherapy in intensive care: an updated systematic review. Chest 2013; 144: 825-847.
84. Clini E, Ambrosino N. Early physiotherapy in the respiratory intensive care unit. Respir Med 2005; 99: 1096-1104.
85. Avendaño M, Güell R. Rehabilitación en pacientes con enfermedades neuromusculares y con deformidades de la caja torácica [Rehabilitation in patients with neuromuscular and chest wall abnormalities]. Arch Bronconeumol 2003; 39: 559-565.
86. Lamy O, Van Melle G, Cornuz J, et al. Clinical management of immunocompetent hospitalized patients with community-acquired pneumonia. Eur J Intern Med 2004; 15: 28-34.
87. Robriquet L, Kipris E, Guery B. Beta-adrenergic modulation of lung fluid balance in acuteP. aeruginosa pneumonia in rats. Exp Lung Res 2011; 37: 453-460.
88. Su X, Robriquet L, Folkesson HG, et al. Protective effect of endogenous beta-adrenergic tone on lung fluid balance in acute bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 2006; 290: L769-L776.
89. Miller CC, Hergott CA, Rohan M, et al. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosapneumonia. J Cyst Fibros 2013; 12: 817-820.
90. Webert KE, Vanderzwan J, Duggan M, et al. Effects of inhaled nitric oxide in a rat model ofPseudomonas aeruginosapneumonia. Crit Care Med 2000; 28: 2397-2405.
91. Jean D, Maître B, Tankovic J, et al. Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance. Crit Care Med 2002; 30: 442-447.
92. Gómez FP, Amado VM, Roca J, et al. Effect of nitric oxide inhalation on gas exchange in acute severe pneumonia. Respir Physiol Neurobiol 2013; 187: 157-163.